Figure 4.
Changes of anticoagulant parameters during the study according to pill type and presence of the factor VLeiden mutation. PS indicates protein S; C4BP, C4b-binding protein; PSAPCind, APC-independent anticoagulant activity of protein S; PCI, protein C inhibitor; and APC-sr, activated protein C sensitivity ratio.